沃达利单抗
Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279)
ChemLeader
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
Quantity
- +
Product Overview
Product Name Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279)
CAS2329669-72-7
Storage condition Avoid repeated freeze-thaw. -80°C for one-year storage.
Security information
Product details

Vudalimab is a fully humanized bispecific antibody that potently inhibits both PD-1 and CTLA-4, key immune checkpoint receptors. It is designed to selectively activate tumor-targeting T cells, enhancing the immune response against cancer.

Related
Sorry, no related items
History
Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279)
Loxapine succinate salt
Luminol (Diogenes reagent)
(S)-Timolol maleate | (S)-L-714,465 maleate | MK 950
MK-2894
Elacestrant (Synonyms: RAD1901)
A-1155463
Secaubryenol
Rosmarinic acid | Labiatenic acid
PEAQX | NVP-AAM077